Corcept targets $3B-$5B in Cushing’s revenue in 2030 as it awaits December 17 relacorilant FDA decision (NASDAQ:CORT)
Corcept Therapeutics (CORT) reported Q3 2026 revenue of $340.5M, reaffirming its 2026 guidance of $1.1B-$1.2B. The company targets $3B-$5B in Cushing’s revenue by 2030, pending an FDA decision on relacorilant on December 17.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data that may shift investor expectations for the company's growth trajectory.
Market read
First‑time earnings and guidance disclosure for a mid‑cap biotech; relevance for traders hinges on guidance versus expectations.
What to watch
Potential upcoming FDA decision on relacorilant could offset guidance concerns.
Background
Corcept Therapeutics disclosed its Q3 2026 earnings and reaffirmed FY guidance ahead of an FDA decision on relacorilant.
Ticker impact
Q3 2026 revenue of $340.5M reported and FY 2026 guidance of $1.1B‑$1.2B reiterated.
potential downside as investors reassess growth outlook
The article provides the first public disclosure of quarterly results and full‑year guidance; without expectation data, the impact is uncertain but likely modestly negative if guidance is seen as weak.
Market effects
Biotech/pharma sector may see modest re‑rating based on Corcept's guidance.
U.S. biotech stocks could experience slight pullback.
Limited; primarily affects Corcept and peers.
Counterpoint
If guidance exceeds hidden analyst forecasts, the stock could rally.
Key entities
- companyCorcept Therapeutics
Biopharma focused on cortisol‑related therapies.
